Rhenman & Partners Asset Management’s Sage Therapeutics SAGE Stock Holding History

Rhenman & Partners Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-115,000	Closed	-$4.97M	–	93
2021 Q4	$4.97M	Hold	115,000	–	–	0.33%	72
2021 Q3	$5.1M	Buy	115,000 +40,000	+53%	+$1.83M	0.36%	75
2021 Q2	$4.26M	Buy	+75,000	New	+$5.3M	0.29%	83
2020 Q2	–	Sell	-50,000	Closed	-$1.44M	–	95
2020 Q1	$1.44M	Hold	50,000	–	–	0.2%	77
2019 Q4	$3.61M	Buy	50,000 +30,000	+150%	+$3.69M	0.4%	71
2019 Q3	$2.81M	Sell	20,000 -1,639	-8%	-$274K	0.35%	69
2019 Q2	$3.96M	Sell	21,639 -30,000	-58%	-$5.12M	0.44%	61
2019 Q1	$8.21M	Sell	51,639 -85,700	-62%	-$12.4M	0.96%	46
2018 Q4	$13.2M	Buy	137,339 +12,600	+10%	+$1.44M	1.5%	34
2018 Q3	$17.6M	Sell	124,739 -4,940	-4%	-$763K	1.77%	24
2018 Q2	$20.3M	Buy	129,679 +34,679	+37%	+$5.44M	2.08%	19
2018 Q1	$15.3M	Sell	95,000 -9,930	-9%	-$1.69M	1.89%	24
2017 Q4	$17.3M	Buy	104,930 +54,930	+110%	+$5.33M	2.34%	10
2017 Q3	$3.12M	Hold	50,000	–	–	0.4%	70
2017 Q2	$3.98M	Sell	50,000 -22,659	-31%	-$1.64M	0.57%	62
2017 Q1	$5.16M	Buy	+72,659	New	+$4.26M	0.82%	48

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Rhenman & Partners Asset Management's SAGE Position: Q1 2022 in Review

Rhenman & Partners Asset Management sold out of Sage Therapeutics (SAGE) in Q1 2022, closing a stake of 115,000 shares — an estimated $4.97M sold.

Rhenman & Partners Asset Management first reported a position in SAGE in Q1 2017 and held it in 16 quarters. The position peaked at $20.3M in Q2 2018. 212 funds tracked by Wall St. Rank hold SAGE as of Q1 2022.

Rhenman & Partners Asset Management reported no remaining Sage Therapeutics position as of Q1 2022 after selling out during the quarter.
Rhenman & Partners Asset Management sold 115,000 Sage Therapeutics shares in Q1 2022, an estimated $4.97M.
Rhenman & Partners Asset Management first reported a position in Sage Therapeutics in Q1 2017 and held it in 16 quarters.
Rhenman & Partners Asset Management's Sage Therapeutics position peaked at $20.3M in Q2 2018.
212 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2022.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2022, filed 13 May 2022.